Dainippon Sumitomo Pharma Announces Launch Of "Replagal(R) 3.5 Mg" For Anderson-Fabry Disease

... Dainippon Sumitomo Pharma Co., Ltd. (DSP) announces the upcoming launch of "Replagal(R) 3.5 mg" (nonproprietary name: Agalsidase Alfa (Genetic Recombination)) hereafter, Replagal. Anderson-Fabry disease is a lysosomal storage disorder caused by congenitally deficient or reduced activity of a-galactosidase-A, a hydrolytic enzyme present in intracellular lysosomes. [click link for full article] ...